Heat shock proteins, such as HSP40, HSP60, HSP70 and HSP90, are known as molecular chaperones because they play a role in helping proteins function properly when cells are under stress. The heat shock response protects cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes (the cell’s recycling system), which could otherwise lead to toxicity and disease.
Our work is focused on making use of the cell-protective properties of HSP70 to create new therapies for rare neurodegenerative diseases.
Orphazyme A/S in restructuring Company announcement No. 25/2022 www.orphazyme.com Company Registration No. 32266355
Orphazyme A/S in restructuring Company announcement No. 24/2022 Inside information www.orphazyme.com Company Registration No. 32266355 KemPharm to acquire Orphazyme assets, including those relating to the development and approval of arimoclomol, for a total of USD 12.8 million in cash and assumed
Orphazyme A/S in restructuring Company announcement No. 23/2022 Inside information www.orphazyme.com Company Registration No. 32266355 C o penhagen, Denmark, April 29 , 2022 – Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company,
Our Research
For Investors & Media
Working at Orphazyme